Clinical Trials
3 trialsNCT04924075 2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04195750 2026-05-14
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03401788 2026-04-13
MK-6482-004
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting